Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to ...

After a company-wide restructuring costing some DKK 9 billion ($1.38 billion), Novo’s path to success lies in its ability to ...

Novo Nordisk (NYSE:NVO) shares have drawn attention recently as investors look for clues about what might be driving the stock's movement this month. In the absence of major headlines, valuation and ...

See why Novo Nordisk A/S stock is primed for a rebound despite recent declines. Click for more about NVO growth catalysts in ...

The latest buyout Novo Nordisk is trying to pull off is putting it in a direct confrontation with another beaten-down ...

Novo Nordisk continues to underperform the S&P 500, with a 42.5% YTD decline versus the index's 16.3% gain. Learn more about NVO stock here.

The bears will point out that Novo Nordisk is losing ground in the GLP-1 market to its most important competitor, Eli Lilly.

The analysts see “meaningful skew to the downside” as around one-third of Roche’s 2030 revenue is at risk from competitors targeting major franchises such as Vabysmo, Perjeta, Hemlibra, Alecensa, and ...